Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL’HIV Trial
The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.
Authors
- Enos Bernasconi (ORCID: https://orcid.org/0000-0002-9724-8373)
- Andreas Limacher (ORCID: https://orcid.org/0000-0002-9094-9476)
- Matthias L. Cavassini (ORCID: https://orcid.org/0000-0003-0933-7833)
- Laurent Arthur Decosterd (ORCID: https://orcid.org/0000-0002-9840-1325)
- Sabine Yerly (ORCID: https://orcid.org/0000-0003-1668-696X)
- Annalisa Marinosci (ORCID: https://orcid.org/0000-0002-8054-0044)
- Gilles Wandeler (ORCID: https://orcid.org/0000-0002-5278-8763)
- Tamara Da Silva (ORCID: https://orcid.org/0000-0002-4010-0992)
- Delphine Sculier (ORCID: https://orcid.org/0000-0002-6741-9813)
- Karin J. Metzner (ORCID: https://orcid.org/0000-0003-4862-1503)
- Marcel Stoeckle (ORCID: https://orcid.org/0000-0002-0088-5078)
- Ranjan Sudan (ORCID: https://orcid.org/0000-0002-4231-242X)
- Alexandra Calmy
- Huldrych F. Günthard (ORCID: https://orcid.org/0000-0002-1142-6723)
- Charlotte Barbieux
- Pietro Vernazza (ORCID: https://orcid.org/0000-0002-6849-6941)
- Dominique L. Braun (ORCID: https://orcid.org/0000-0003-4036-1030)
- Mattia Branca
- Patrick Schmid (ORCID: https://orcid.org/0000-0003-1978-5082)
- Beatrice Bernasconi-Meyer
Institutions
- University of Geneva (CH)
- University of Bern (CH)
- Bern University of Applied Sciences (CH)
- University of Applied Sciences and Arts of Southern Switzerland (CH)
- University of Basel (CH)
- University of Zurich (CH)
- Kantonsspital St. Gallen (CH)
- University Hospital of Bern (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- University Hospital of Basel (CH)
- Laboratory for Biomedical Neurosciences (CH)
- Ente Ospedaliero Cantonale (CH)
- University Hospital of Zurich (CH)
- University Hospital of Geneva (CH)
- Institute of Social and Preventive Medicine (CH)
- Geneva College (US)
- University of Lausanne (CH)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1093/ofid/ofae618
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- National Science Foundation
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- ViiV Healthcare
- Moderna
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Institutes of Health
- Merck Sharp and Dohme